Pluristem CEO Zami Aberman to Present at Two Regenerative Medicine Conferences in London on November 12 and 13, 2014

London Regenerative Medicine Network Meeting

Alliance for Regenerative Medicine's 2nd Annual European Advanced Therapies Investor Day

HAIFA, ISRAEL, November 10th, 2014 -- Pluristem Therapeutics Inc. (NasdaqCM: PSTI; TASE: PLTR), a leading developer of placenta-based cell therapy products, announced today that the Company's CEO, Zami Aberman, has been invited to present at two regenerative medicine conferences in London regarding Pluristem's cell therapy platform, large-scale manufacturing methods, and intellectual property strategy.

At the London Regenerative Medicine Network's (LRMN) November 12 meeting, Mr. Aberman will deliver a presentation titled, "Maturing adherent-cell therapies for commercialization: strategies, technology barriers and possible solutions." Mr. Aberman is one of three international speakers invited to present on the topic of scalable manufacturing therapies, which will be the focus of LRMN's November 2014 meeting sponsored by Thermo Fisher Scientific.

Mr. Aberman will also present at the Alliance for Regenerative Medicine's (ARM) 2nd Annual European Advanced Therapies Investor Day on November 13. His presentation, entitled "The Placenta as a superior source for cell therapy products – strategy and implementation", will focus on Pluristem's proprietary three-dimensional cell expansion technology platform, and the Company's unique methods for developing and manufacturing distinct cell therapy products to treat specific diseases. Mr. Aberman will also discuss Pluristem's successful intellectual property strategy, which serves as a model for IP protection in the regenerative medicine industry.

About Pluristem Therapeutics

Pluristem Therapeutics Inc. is a leading developer of placenta-based cell therapy products. The Company's patented PLX (PLacental eXpanded) cells release a cocktail of therapeutic proteins in response to inflammation, hematological disorders, radiation damage, and ischemia. PLX cells are grown using the Company's proprietary three-dimensional expansion technology and are an "off-the-shelf" product that requires no tissue matching prior to administration.

Pluristem has a strong intellectual property position, Company-owned GMP certified manufacturing and research facilities, strategic relationships with major research institutions and a seasoned management team. For more information visit www.pluristem.com, the content of which is not part of this press release.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and federal securities laws. For example, forward-looking statements are used in this press release when we discuss our potential to develop cell therapy products to treat specific diseases, and that Pluristem's IP assets will in fact protect its position in the regenerative medicine industry. These forward-looking statements and their implications are based on the current expectations of the management of Pluristem only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; we may encounter delays or obstacles in launching and/or successfully completing our clinical trials; our products may not be approved by regulatory agencies, our technology may not be validated as we progress further and our methods may not be accepted by the scientific community; we may be unable to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties may develop with our process; our products may wind up being more expensive than we anticipate; results in the laboratory may not translate to equally good results in real surgical settings; results of preclinical studies may not correlate with the results of human clinical trials; our patents may not be sufficient; our products may harm recipients; changes in legislation; inability to timely develop and introduce new technologies, products and applications; loss of market share and pressure on pricing resulting from competition, which could cause the actual results or performance of Pluristem to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Pluristem undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Pluristem, reference is made to Pluristem's reports filed from time to time with the Securities and Exchange Commission.

Contact:

Pluristem Therapeutics Inc.:

Karine Kleinhaus, MD, MPH
Divisional VP, North America
1-914-512-4109
karinek@pluristem.com